《美股業績》吉利德科學(GILD.US)愛滋病藥季度銷售勝預期 惟下調全年盈測
藥廠吉利德科學(Gilead Sciences)(GILD.US)公佈第二季業績。季度純利按年跌8.7%至10.45億美元。每股季度攤薄純利83美仙,經調整後爲1.34美元,差於市場預期的1.64美元,每股季度派息75美仙。季度總收益按年升5.4%至65.99億美元,市場預期爲64.4億美元。
公司預期旗下新冠藥瑞德西韋全年銷售17億美元,低於原先預期的20億美元。愛滋病藥物組合季度銷售按年升9%至46.3億美元,其中Biktarvy季度銷售29.8億美元,高於市場預期的28.5億美元。公司同時爲愛滋病藥反壟斷訴訟作出和解,導致盈利減少5.25億美元或每股32美仙。
公司下調全年經調整盈利預測,由每股介乎6.6至7美元,降至每股介乎6.45至6.8美元,全年收入預測下限則由260億美元上調至263億美元,上限預測維持267億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.